- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
NanoViricides, Inc., a nano-biopharmaceutical company specializing in the development of novel therapeutics to treat life-threatening viral infections, announced today that it has joined the Alliance for Biosecurity, an association comprised of a leading non-profit biosecurity organization and 14 other biopharmaceutical companies committed to improving the nation's biosecurity through the development of medical countermeasures to address a range of bioterrorism and natural pandemic threats.
Anita Cicero, Executive Director of the Alliance for Biosecurity, commented, "We are delighted to welcome NanoViricides into the Alliance. The company's work in the cutting-edge field of Nanomedicine, combined with its interest in contributing constructive policy suggestions to bolster national Flexible Defense initiatives, will be a significant asset to the Alliance. NanoViricides shares our organization's goal of rapidly accelerating the research, development, and procurement of medical countermeasures that will be needed to respond to both destabilizing pandemics and bioterrorism attacks. With NanoViricides' help, the Alliance will continue its efforts to maximize the promise of Project BioShield and the new Pandemic and All Hazards Preparedness Act."
"Our Rapid Response technologies fit in well with the Flexible Biodefense initiatives that are part of recent US Government acts," said Anil R. Diwan, Ph.D., President, NanoViricides, Inc.
"NanoViricides is honored to be associated with this prestigious organization whose strong membership, comprised of the principal actors in the BioSecurity field, includes some of the most prestigious pharma and biotechnology companies in the world," added Dr. Eugene Seymour, CEO, NanoViricides, Inc.
In other news, NanoViricides, Inc. announced that it has been informed that the nominating NASD member firm has responded to NASD comments on the form 15c2-11submission for NanoViricides to be listed on the over the counter bulletin board (OTC-BB).
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
About the Alliance for Biosecurity- http://www.allianceforbiosecurity.org
The Alliance for Biosecurity is a collaboration among the Center for Biosecurity of the University of Pittsburg Medical Center, pharmaceutical companies, and biotechnology companies working to develop new technologies and vaccines and medicines for the Strategic National Stockpile. The Alliance seeks to engage government in a public-private partnership to usher in a new era in the prevention and treatment of severe infectious diseases that present global security threats. Member companies of the Alliance now include: Acambis, Inc., Avecia Biotechnology, Bavarian-Nordic, Cangene Corporation, DOR BioPharma, Inc., DynPort Vaccine Company, LLC, a CSC company, Elusys Therapeutics, Inc., Emergent BioSolutions, GlaxoSmithKline, Human Genome Sciences, Inc., Iomai Vaccines, NanoViricides, Inc., Novartis Vaccines & Diagnostics, Pfizer Inc., and PharmAthene, Inc.
For more information, please click here
Leo Ehrlich, 917-853-6440
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Nanoparticles that speed blood clotting may someday save lives August 23rd, 2016
Researchers reduce expensive noble metals for fuel cell reactions August 22nd, 2016
Spider silk: Mother Nature's bio-superlens August 22nd, 2016
Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016
Thomas Swan and NGI announce unique partnership July 28th, 2016